Investment in R&D
|CSL is investing in the development of new protein-based medicines for treating serious human diseases as an important avenue to future growth. We have increased our investments significantly over recent years. In 2011/12 we invested A$368 million in our R&D programs and this will continue to increase in 2012/2013. |
R&D investment remains an important avenue to future growth for CSL. We now have a high quality and potentially valuable portfolio of projects in various stages of development. We continue to make a balanced investment in life cycle management and market development of existing products that bring short to mid term commercial benefits, as well as strategic investments in longer term, higher risk and high opportunity new product development activities in areas aligned with our core capabilities and commercial strengths.
CSL Research and Development Investment (US$ Millions)